Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential

Prostate

Volumn 68, Issue 8, 2008, Pages 830-838

  Ricciardelli, Carmela ^a   Jackson, Michael W ^b   Choong, Catherine S ^a,e   Stahl, Jürgen ^c   Marshall, Villis R ^d   Horsfall, David J ^a   Tilley, Wayne D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c Adelaide Pathology Partners   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

Androgen receptor; HER 2 neu; Prostatic neoplasms; Radical prostatectomy

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

AGED; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN;

EID: 45349108158     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20747     Document Type: Article

References (51)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707-712.
2. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA Jr, Ullrich A. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J Clin Immunol 1991;11(3):117-127.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses H ER2. N Engl J Med 2001;344(11):783-792.
4. Myers RB, Srivastava S, Oelschlager DK, Grizzle WE. Expression of pl60erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 1994;86(15):1140-1145.
5. Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman RP Jr, Fisher HA, Rifkin MD, Muraca PJ. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997;79(11):2162-2170.
6. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92(23):1918-1925.
7. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001;7(9):2643-2647.
8. Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ. Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001;166(4):1514-1519.
9. Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, Gregory CW, Lin Y, Whang YE, Earp HS, Mohler JL. Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 2003;9(3):1087-1097.
10. Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, Lopez Beltran A. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: Comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol 2006;37(9):1137-1144.
11. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 2001;116(2):234-239.
12. Lara PN Jr, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, Tichauer G, Twardowski P, Doroshow JH, Gandara DR. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer 2002;94(10):2584-2589.
13. Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'Armiento M, Bianco AR, De Placido S. HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori 2004;90(2):163-170.
14. Nishio Y, Yamada Y, Kokubo H, Nakamura K, Aoki S, Taki T, Honda N, Nakagawa A, Saga S, Hara K. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 2006;68(1):110-115.
15. Oxley JD, Winkler MH, Gillatt DA, Peat DS. Her-2/neu oncogene amplification in clinically localised prostate cancer. J Clin Pathol 2002;55(2):118-120.
16. Ullen A, Lennartsson L, Harmenberg U, Lennernas B, Majumder K, Holmberg AR, Nilsson S, Elmberger GP. Prostate cancer cell lines lack amplification: Overexpression of H ER2. Acta Oncol 2005;44(5):490-495.
17. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer 2003;89(5):899-906.
18. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20(3-4):207-223.
19. Whitfield GK, Jurutka PW, Haussler CA, Haussler MR. Steroid hormone receptors: Evolution, ligands, and molecular basis of biologic function. J Cell Biochem 1999;Suppl 32-33:110-122.
20. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-39.
21. Van Der Kwast TH, Schalken J, Ruizeveld DWJ, van Vroonhoven CC, Mulder E, Boersma W, Trapman J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991;48(2):189-193.
22. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995;55(14):3068-3072.
23. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH, Van Der Kwast TH. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994;144(4):735-746.
24. Gil-Diez de Medina S, Salomon L, Colombel M, Abbou CC, Bellot J, Thiery JP, Radvanyi F, Van der Kwast TH, Chopin DK. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 1998;29(9):1005-1012.
25. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61(9):3550-3555.
26. Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, Marshall VR, Horsfall DJ, Tilley WD. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 2005;63(1):19-28.
27. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: Cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004;28(7):928-934.
28. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11(3):459-476.
29. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60(24):6841-6845.
30. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004;6(5):517-527.
31. Hermanek P, Sobin LH. International Union Against Cancer (IUCC). Urological Tumours: Prostate. TNM Classification of Urological Tumours. 4th edition, New York: Springer-Verlag; 1992. p 141.
32. Zhang SX, Bentel JM, Ricciardelli C, Horsfall DJ, Haagensen DE, Marshall VR, Tilley WD. Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers. J Urol 1998;159(2):548-554.
33. Dako. Dako HercepTest Facts. Glostrup, Denmark: Dako; 1999.
34. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001; Jun 7(6):1669-1675 2001.
35. Troyer JK, Beckett ML, Wright GL Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997;30(4):232-242.
36. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin- like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54(20):5474-5478.
37. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999;96(10):5458-5463.
38. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5(3):280-285.
39. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by IL-6 and the role of the coactivator SRC-1 in prostate cancer cells. J Biol Chem 2002;277(41):38087-38094.
40. Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res 2007;13(18 Pt 1):5377-5384.
41. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002;94(4):980-986.
42. Goldstein NS, Hunter S, Forbes S, Odish E, Tehrani M. Estrogen receptor antibody incubation time and extent of immunoreactivity in invasive carcinoma of the breast: The importance of optimizing antibody avidity. Appl Immunohistochem Mol Morphol 2007;15(2):203-207.
43. Sanchez KM, Sweeney CJ, Mass R, Koch MO, Eckert GJ, Geary WA, Baldridge LA, Zhang S, Eble JN, Cheng L. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: A requested for a standardized, organ specific methodology. Cancer 2002;95(8):1650-1655.
44. Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: Final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004;100(10):2125-2131.
45. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N. 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8(5):986-993.
46. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006;13(Suppl 1):S125-S135.
47. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004;60(4):332-337.
48. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23(3):455-460.
49. de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 2007;25(3):257-262.
50. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 2006;66(11):5723-5728.
51. Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp HS, Whang YE. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 2005;65(8):3404-3409.